Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

BACKGROUND: Erdheim–Chester disease (ECD), a rare inflammatory myeloid neoplasm, is known to be fundamentally reliant on the constitutive activation of the MAPK signaling pathway in the majority of patients. Consequently, inhibition of the V600E-mutant BRAF kinase has proven to be a safe and efficac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Mazor, Roei D, Weissman, Ran, Luckman, Judith, Domachevsky, Liran, Diamond, Eli L, Abdel-Wahab, Omar, Shapira, Shirley, Hershkovitz-Rokah, Oshrat, Groshar, David, Shpilberg, Ofer
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212923/
https://ncbi.nlm.nih.gov/pubmed/32642685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados